The present invention relates to a particular diarylhydantoin compound acting by reducing the androgen-receptor(AR) activity. The compound is thus for use in treatment of diseases such as hormone refractory cancer, prostate cancer, benign prostate hyperplasia, breast cancer and ovarian cancer.